CLOs on the Move

Envision Healthcare

www.envisionhealth.com

 
Envision Healthcare is on the front lines of change. Through our primary business units – Envision Physician Services, Evolution Health and AMSURG – our clinician-led organization is changing the face of healthcare by delivering high-quality care that elevates the patient experience. Envision Healthcare is pioneering solutions to the toughest challenges in healthcare. We serve as a partner to help navigate the constantly evolving landscape of healthcare delivery, and we are vigilant in working with health systems and hospitals to identify opportunities to better serve our communities. Our physicians, advanced practice providers and support teams are responsible for more than 30 ...
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
Patrick Velliky
 Senior Vice President Government Affairs Profile
Carrie Damon
 Chief Information Officer Profile
Chandra Westergaard
 Vice President, Associate General Counsel - Government and Regulatory Matters Profile
Marc Bonora
 Vice President, Associate General and Chief Litigation Counsel Profile
Justin Page
 Vice President, Associate General and Chief Operations Counsel Profile

Similar Companies

BMC Communications Group

BMC Communications Group is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Affordable Health Choice Inc

Affordable Health Choice Inc is a Fort Lauderdale, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Condor (Canada) Medical Co.

Condor (Canada) Medical Co., Ltd. is a Abbotsford, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Nursing Resources

Nursing Resources is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Envisia Therapeutics

Envisia Therapeutics, formed by Liquidia Technologies in 2013, is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® platform to develop therapies for a variety of ocular conditions, the most advanced of which is ENV515, for the treatment of glaucoma. ENV515 is a novel extended-release formulation of a prostaglandin analogue formulation. It has the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. Envisia is located in Research Triangle Park, North Carolina.